NCT03296618Unknown1 期
Phase I Clinical Study of Intracerebral Transplantation of Neural Stem Cells for the Treatment of Ischemic Stroke
Suzhou Neuralstem Biopharmaceuticals1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2012年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Adverse Events
研究概览
简要总结
The study is to determine the safety of human neural stem cell transplantation for the treatment of paralysis and related symptoms due to chronic motor stroke and to determine the maximum tolerated dose.
详细描述
This is a Phase I study of human neural stem cell transplantation for the treatment of chronic motor stroke. This single-site, Phase I, open-label study may enroll up to 18 patients across 5 cohorts of ascending doses of human neural stem cells to define maximal tolerated dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have the ability to understand the requirements of the study, provide written informed consent, understand and provide written authorization for the use and disclosure of Protected Health Information (PHI) [per Health Insurance Portability and Accountability Act (HIPAA) Privacy Ruling] and comply with the study procedures
- •Men and women 30-65 years old
- •Women must have a negative serum pregnancy test and practice an acceptable method of contraception or be of non-childbearing potential (post-menopausal for at least 2 years or who have undergone hysterectomy or oophorectomy or surgical sterilization)
- •At least 3 months but no more than 24 months from time of stroke, with a motor neurological deficit
- •Documented history of completed ischemic stroke in subcortical region of MCA or lenticulostriate artery with or without cortical involvement, with correlated findings by MRI
- •Modified Rankin Score of 2, 3 or 4
- •FMMS score of 55 or less;
- •Two evaluations at approximately 3 weeks apart prior to surgery with less than +/- 4 point change in the NIHSS
- •Able and willing to meet all follow-up requirements
- •Able and willing to undergo post-physical therapy/rehabilitation
排除标准
- •Any disabling psychological or psychiatric disorders which may confound the study
- •History of more than one symptomatic stroke, TIAs allowed
- •History of another major neurological disease or injury
- •Cerebral infarct size >8cm in any one measurement
- •Myocardial infarction within the prior 3 months
- •History of seizures or current use of antiepileptic medication
- •Receipt of any investigational drug or device within 30 days
- •Receipt of any cell infusion other than blood transfusion
- •Any concomitant medical disease or condition noted below:
- •Coagulopathy with INR > 1.4 at the time of surgery
- •Panel Reactive Antibodies (PRA) > 20% at initial screen
- •Active infection at the time of surgery
- •Active hypotension requiring vasopressor therapy
- •Skin breakdown over the site of surgery
- •Active or history of malignancy
- •Primary or secondary immune deficiency
- •Persistent MRI artifact that would prevent imaging pre and post-operation or unable to undergo MRI
- •Creatinine >115μmol/L, liver function tests (SGOT/SGPT, Bilirubin, Alk Phos) > 2x upper limit of normal, hematocrit/hemoglobin < 30/10, total WBC < 4000/mm3,platelet count <100,000/mm3, uncontrolled hypertension (systolic > 180mmHg or diastolic> 100mmHg) or uncontrolled diabetes (defined as hemoglobin A1C>8%), evidence of GI bleeding by hemoccult test,positive tuberculosis (TB test: PPD/Mantoux), hepatitis B or C, or human immunodeficiency virus (HIV)
- •Presence of any of the following conditions:
- •Current drug abuse or alcoholism
- •Unstable medical conditions
- •Unstable psychiatric illness including psychosis and untreated major depression
- •Any condition that the Investigator or primary physician feels may interfere with participation in the study or may endanger the subject
- •Any condition that the surgeon feels may pose complications for the surgery
- •Known hypersensitivity to tacrolimus or methylprednisolone
- •Unable or unwilling to participate in physical and/or occupational therapy or return to clinic for follow up examinations as scheduled
- •Inability to provide informed consent as determined by screening protocol.
- •Use of antiplatelet drugs less than 2 weeks before surgery
研究组 & 干预措施
NSI-566 neural stem cell implantation
Experimental
干预措施: NSI-566 (Drug)
结局指标
主要结局
Adverse Events
时间窗: 24 months
次要结局
- Clinical improvement using NIH Stroke Scale(12 months)
- Clinical improvement using Modified Rankin Scale(12 months)
- Clinical Improvement using Mini-mental State Examination(12 months)
- Clinical improvement using Fugl-Meyer Motor Score(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Intracerebral Transplantation of Autologous MSC Combined With Scaffold Product for Chronic Intracerebral HemorrhageIntracerebral HemorrhageNCT06361433Hokkaido University Hospital8
终止
2 期
Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord InjurySpine InjuryCervical Spine InjuryCervical Spinal Cord InjuryNCT02163876StemCells, Inc.31
Unknown
1 期
Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's DiseaseParkinson's DiseaseNCT03119636Chinese Academy of Sciences50
已完成
1 期
Neural Stem Cell Transplantation in Multiple Sclerosis PatientsProgressive Multiple SclerosisNCT03269071IRCCS San Raffaele4
Unknown
1 期
Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCISpinal Cord Injury (SCI)NCT01772810Neuralstem Inc.8